Skip to main content
ERYTECH Pharma S.A. logo

ERYTECH Pharma S.A. — Investor Relations & Filings

Ticker · ERYP ISIN · FR001400K4B1 LEI · 969500U8ZZCODU8A9374 PA Manufacturing
Open in API
Filings indexed 864 across all filing types
Latest filing 2025-03-06 Legal Proceedings Report
Country FR France
Listing PA ERYP

About ERYTECH Pharma S.A.

https://phaxiam.com/

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Legal Proceedings Report Classification · 1% confidence The document is titled "PHAXIAM THERAPEUTICS Announces the Opening of a Receivership Procedure and the Postponement of its 2024 Financial Results Publication" and is explicitly labeled as a "PRESS RELEASE". It details a significant corporate event (opening of a judicial receivership procedure) and an update regarding a future financial report publication date (postponement of 2024 results). Since it is an announcement about a major corporate event and regulatory status change, and not the full financial report itself (like a 10-K or IR), it fits best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS). It is not an Earnings Release (ER) as it focuses on legal/financial distress and postpones the results, nor is it a Call Transcript (CT) or Investor Presentation (IP). Given the nature of the announcement (receivership, trading suspension), RNS is the most appropriate general regulatory filing category.
2025-03-06 English
Inside Information / Other news releases
Delisting Announcement Classification · 1% confidence The document is a short press release titled "PRESS RELEASE REGARDING SUSPENSION OF TRADING." It explicitly states that PHAXIAM Therapeutics has requested Euronext to suspend trading pending the release of an upcoming press release. This is a specific, immediate corporate action announcement that is not covered by the detailed financial reports (10-K, IR, ER) or specific corporate governance filings (DEF 14A, DVA). Since it is a regulatory-related announcement that doesn't fit the other specific categories (like Delisting, Director's Dealing, or Dividend), the most appropriate fallback category is Regulatory Filings (RNS), as it serves as a general regulatory announcement regarding market activity.
2025-03-06 English
Informations privilégiées / Autres communiqués
Delisting Announcement Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE RELATIF A LA SUSPENSION DE COURS" (Press Release Regarding Trading Suspension). It explicitly states that PHAXIAM Therapeutics requested Euronext to suspend the trading of its stock pending the release of a future press release. This is a specific regulatory/market announcement concerning the trading status of the stock, not a full financial report (like 10-K or IR) or a standard earnings release (ER). Since the document announces a specific market action (trading suspension) that is not covered by the more specific codes (like DIV, SHA, CAP), it falls best under the general regulatory announcement category, RNS (Regulatory Filings), as it is a mandatory disclosure to the market regarding trading status.
2025-03-06 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release from PHAXIAM Therapeutics providing a strategic update on their business model, clinical development, and financial outlook. It discusses the deployment of their IPT and PTMP models, a strategic collaboration with Technophage, and provides preliminary cash position data. It is not a formal financial report (10-K or IR), nor is it a simple announcement of a report (RPA). It functions as a corporate update on strategy and operations, which falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-01-31 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from PHAXIAM Therapeutics titled 'PHAXIAM fait le point sur le déploiement de sa stratégie'. It details the company's business strategy, including a new partnership with Technophage, updates on clinical trials (GLORIA), and preliminary financial information (cash position as of Dec 31, 2024). It is not a full annual report, nor is it a simple announcement of a report publication; it is a substantive corporate update on business operations and strategy, which falls under the category of Management Reports (MDA) as it provides management's detailed explanation of business trends, outlook, and strategic direction.
2025-01-31 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release announcing a strategic collaboration between PHAXIAM Therapeutics and Technophage. It details the nature of the partnership, including shared resources, production capabilities, and clinical development goals. It does not fit into specific financial reporting categories like 10-K or ER, nor is it a simple report publication announcement (RPA) as it provides substantive details of the business agreement. Therefore, it is classified as a general regulatory filing/announcement.
2025-01-30 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.